About Stem Cell Therapy for Traumatic Brain Injury
Preliminary Introduction
Traumatic Brain Injury (TBI) is a condition characterized by damage to brain tissue caused by a forceful impact to the head, often resulting from traffic accidents, falls, or similar incidents. In severe cases, it can lead to serious symptoms such as loss of consciousness, memory loss, hemiplegia, or speech impairment, and frequently results in permanent, lifelong disabilities.
Presently, TBI patients and their families focus on acute intervention during the acute phase and functional recovery through rehabilitation. However, they confront the challenge that "damaged brain cells do not regenerate." Indeed, there is no scientific evidence that dead or damaged brain cells regenerate into new cells. While the remaining brain regions make significant efforts to compensate for lost functions, deficits often persist in motor skills, cognitive function, and speech, as well as personality changes and symptoms of depression.
Such impairments significantly diminish the quality of life (QOL) and impose a substantial burden on patients and their families.
Traumatic Brain Injury (TBI) and Current Treatment Challenges
Current standard management for Traumatic Brain Injury (TBI) primarily focuses on emergency care in the acute phase and subsequent rehabilitation. For instance, immediately following the injury, surgical intervention and intensive care are provided, including hematoma evacuation and intracranial pressure control. This is then followed by physical and occupational therapy to maximize and enhance residual function.
However, once brain tissue sustains serious damage, it is inherently challenging to fully restore it to normal function through medication or rehabilitation alone. The brain is a notoriously difficult organ to heal, and to date, no medical treatment has successfully regenerated nerve cells within the damaged areas.
Consequently, despite many patients achieving some improvement through rehabilitation, they continue to live with some form of long-term disability, such as paralysis or memory impairment. The current therapeutic challenge lies in the question of how to regenerate these lost brain cells. Patients and their families eagerly desire new treatments that can fundamentally repair the brain.
New Possibilities in Stem Cell Therapy and Regenerative Medicine for Traumatic Brain Injury
In recent years, stem cell therapy, a form of regenerative medicine, has garnered significant attention. Stem cell therapy is a cutting-edge medical treatment that utilizes stem cells—naturally occurring cells in our bodies that are the source of various cell types—to promote the repair and regeneration of damaged tissues. Even in cases of previously untreatable brain damage, stem cells are expected to leverage the body's intrinsic healing capabilities to restore lost brain function.
Specifically, Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) have garnered significant attention in recent years. Wharton's jelly is a gelatinous substance found in the umbilical cord, collected at birth. The stem cells contained within it are nascent, possessing exceptionally high regenerative capabilities. They possess the ability to differentiate into various cell types and exhibit superior proliferative capacity. Coupled with minimal ethical concerns and high immunocompatibility, they present virtually no risk of rejection even when derived from allogeneic sources, thus being considered safe stem cells.
These "highest potential stem cells" are a focal point of regenerative medicine research worldwide, and remarkable effects have been reported in numerous clinical trials. Our institution also utilizes Wharton's jelly-derived stem cells for treatment, aiming for enhanced therapeutic effects by harnessing the cells' maximum potential. Novel stem cell therapy options are increasingly emerging as a beacon of hope for brain repair in patients suffering from Traumatic Brain Injury (TBI).
Mechanism of Action of Stem Cell Therapy for Traumatic Brain Injury
Tissue Regeneration in the Damaged Area
Transplanted stem cells facilitate a form of "brain repair." These stem cells differentiate into neural or vascular cells as needed, generating new cells and filling gaps in damaged tissue. Imagine a construction crew repairing potholes in a road. Stem cells are akin to the workers in this repair process, producing new cells (like laying fresh asphalt) incrementally, and seamlessly resurfacing the "potholed road" (brain circuits). Through this mechanism, brain tissue, which is otherwise considered non-regenerative, is restored, potentially leading to functional recovery.
Stem Cell Therapy for Traumatic Head Injury
Activating surrounding cells
Stem cells not only differentiate into new cells but also act as a conductor, signaling surrounding cells to "collaborate for repair!" Indeed, it is reported that substances such as cytokines and growth factors released from stem cells promote the survival of surrounding nerve cells and activate the function of endogenous neural stem cells within the brain. Analogously, stem cells become the "leader of a reconstruction team dispatched to a damaged city," engaging with the residents (remaining cells) in the vicinity to stimulate the overall recovery of the city (overall improvement in brain function).
Excessive Suppression of Inflammation (Immunomodulatory Action)
Residence
In Traumatic Brain Injury (TBI), the body's immune system is activated immediately post-injury, initiating an inflammatory response. While a moderate inflammatory response is necessary to address the damaged area, excessive inflammation leads to "secondary injury," which further harms brain cells. In this context, stem cells play a crucial inhibitory role, modulating the detrimental immune response. Specifically, Wharton's Jelly-derived Mesenchymal Stem Cells (WJ-MSCs) have been confirmed to possess prominent anti-inflammatory effects by suppressing pro-inflammatory substances (cytokines) and alleviating swelling and tissue damage. Simply put, much like a firefighter dousing an unnecessarily spreading blaze, stem cells extinguish this inflammatory "fire." Consequently, the cerebral microenvironment is stabilized, establishing conditions conducive to healing.
Furthermore, stem cells possess the ability to precisely control immune function and actively prevent their identification as foreign bodies, thereby avoiding attack. Consequently, transplanted stem cells readily engraft and can be safely utilized for therapeutic purposes. Thus, stem cell therapy exerts multifaceted effects on the damaged brain. These actions—including the repair of damaged areas, the supply of new cells, the release of paracrine repair signals, and the suppression of excessive inflammation—make it possible to improve brain functions that were previously considered irrecoverable. It can truly be asserted that "stem cells are the body's intrinsic repair and regulatory specialists."
Evidence of Effectiveness of Stem Cell Therapy for Traumatic Brain Injury
Clinical Trial Achievements for Chronic TBI Patients (SB623)
An international clinical trial utilizing the stem cell therapy "SB623," developed by the Japanese company Sanbio, demonstrated significant improvement in motor function among chronic TBI patients who were 6 months to several years post-injury. In this trial, 39.1% of the group receiving intracerebral stem cell transplantation achieved a large, clinically meaningful improvement in their Fugl-Meyer Motor Scale (FMMS) scores for paralyzed upper and lower extremities (+10 points or more), significantly exceeding the 6.7% observed in the control group.
Experts commented that the findings of this experiment are highly groundbreaking, demonstrating the potential for damaged brains to regenerate. This provides evidence that regenerative medicine is effective even for chronic neurological conditions previously considered intractable. Stem cell therapy has thus emerged as a novel therapeutic option for brain conditions previously deemed beyond recovery.
In this experiment, the observed improvement was not transient; significant recovery was reported to be maintained even at the 1-year follow-up. This indicates that the enhancement in motor function achieved through stem cell therapy was sustained for at least one year, and the level of independence in activities of daily living improved...
Preliminary Introduction
For patients and their families, the prospect of improved brain function, even after a considerable period, offers immense hope.
Traumatic Brain Injury (TBI) is a condition characterized by damage to brain tissue caused by a forceful impact to the head, often resulting from traffic accidents, falls, or similar incidents. In severe cases, it can lead to serious symptoms such as loss of consciousness, memory loss, hemiplegia, or speech impairment, and frequently results in permanent, lifelong disabilities.
Findings from Other Clinical Studies
Presently, TBI patients and their families focus on acute intervention during the acute phase and functional recovery through rehabilitation. However, they confront the challenge that "damaged brain cells do not regenerate." Indeed, there is no scientific evidence that dead or damaged brain cells regenerate into new cells. While the remaining brain regions make significant efforts to compensate for lost functions, deficits often persist in motor skills, cognitive function, and speech, as well as personality changes and symptoms of depression.
Beyond the above, numerous clinical studies conducted globally have shown promising results for stem cell therapy. For example, in a study conducted in China involving 20 patients with traumatic brain injury, umbilical cord-derived stem cells (such as Wharton's Jelly mesenchymal stem cells, or WJ-MSCs, derived from newborns) were injected four times into the cerebrospinal fluid, and six months later, extremity motor function, sensation, and balance...
Such impairments significantly diminish the quality of life (QOL) and impose a substantial burden on patients and their families.
Meanwhile, the control group that did not receive stem cell injections demonstrated no such improvement, and a clear difference emerged between the two groups. In another small-scale trial, when autologous bone marrow stem cells were transplanted to the site of injury in 7 patients, an improvement in neurological function was observed in all participants, and no serious side effects were reported.
Traumatic Brain Injury (TBI) and Current Treatment Challenges
Subsequently, in a relatively large-scale study of 97 participants, neurological improvement was observed in approximately 40% of patients upon evaluation 2 weeks following a single administration of autologous stem cells to patients 1-3 months post-trauma.
Current standard management for Traumatic Brain Injury (TBI) primarily focuses on emergency care in the acute phase and subsequent rehabilitation. For instance, immediately following the injury, surgical intervention and intensive care are provided, including hematoma evacuation and intracranial pressure control. This is then followed by physical and occupational therapy to maximize and enhance residual function.
In this context, the restoration of function has been confirmed in several studies, and its overall safety profile is also considered favorable. Naturally, as each study varies in scale and design, there are variations in the observed levels of effectiveness. Crucially, however, there have been no reports indicating a deterioration of conditions following stem cell therapy; on the contrary, specific improvements have been demonstrated.
However, once brain tissue sustains serious damage, it is inherently challenging to fully restore it to normal function through medication or rehabilitation alone. The brain is a notoriously difficult organ to heal, and to date, no medical treatment has successfully regenerated nerve cells within the damaged areas.
Furthermore, regarding WJ-MSCs derived from Wharton's jelly, it is reported that remarkable effects continue to be demonstrated worldwide, and it is anticipated that in the future, their application will extend not only to TBI but also to a variety of neurological disorders.
Consequently, despite many patients achieving some improvement through rehabilitation, they continue to live with some form of long-term disability, such as paralysis or memory impairment. The current therapeutic challenge lies in the question of how to regenerate these lost brain cells. Patients and their families eagerly desire new treatments that can fundamentally repair the brain.
Based on this evidence, it can be stated that stem cell therapy for TBI is a promising treatment with a reasonable likelihood of efficacy.
New Possibilities in Stem Cell Therapy and Regenerative Medicine for Traumatic Brain Injury
In recent years, stem cell therapy, a form of regenerative medicine, has garnered significant attention. Stem cell therapy is a cutting-edge medical treatment that utilizes stem cells—naturally occurring cells in our bodies that are the source of various cell types—to promote the repair and regeneration of damaged tissues. Even in cases of previously untreatable brain damage, stem cells are expected to leverage the body's intrinsic healing capabilities to restore lost brain function.
Safety and Adverse Effects of Stem Cell Therapy for Traumatic Brain Injury
Indeed, research and clinical trials on stem cell therapy for TBI are underway worldwide, with new regenerative medicine products continuously being developed. For instance, efforts are ongoing to transplant stem cells into damaged brain tissue and restore functions previously assumed by other brain regions by "regenerating the lost cells themselves." Through such novel possibilities offered by regenerative medicine, it is anticipated that severe post-traumatic disabilities may be avoided in the future.
When evaluating novel therapeutic approaches, safety is a primary concern for patients and their families. Numerous clinical studies have reported a high safety profile for stem cell therapy.
Specifically, Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) have garnered significant attention in recent years. Wharton's jelly is a gelatinous substance found in the umbilical cord, collected at birth. The stem cells contained within it are nascent, possessing exceptionally high regenerative capabilities. They possess the ability to differentiate into various cell types and exhibit superior proliferative capacity. Coupled with minimal ethical concerns and high immunocompatibility, they present virtually no risk of rejection even when derived from allogeneic sources, thus being considered safe stem cells.
Given that stem cell therapy involves the direct introduction of cells into the body, it is natural to question potential side effects and the possibility of rejection reactions. In this regard, numerous clinical studies have reported a high safety profile for stem cell therapy. Firstly, a key characteristic of stem cells themselves, particularly mesenchymal stem cells derived from Wharton's jelly, is their low immunogenicity, which results in virtually no risk of rejection reactions. This is because even allogeneic cells are not readily recognized as foreign bodies within the patient's system and are not targeted by the immune system.
These "highest potential stem cells" are a focal point of regenerative medicine research worldwide, and remarkable effects have been reported in numerous clinical trials. Our institution also utilizes Wharton's jelly-derived stem cells for treatment, aiming for enhanced therapeutic effects by harnessing the cells' maximum potential. Novel stem cell therapy options are increasingly emerging as a beacon of hope for brain repair in patients suffering from Traumatic Brain Injury (TBI).
Typically, organ transplantation necessitates strong immunosuppressive drugs to prevent rejection reactions. However, in the case of Wharton's jelly mesenchymal stem cells (WJ-MSCs), the associated burden can be lessened, resulting in superior safety.
Mechanism of Action of Stem Cell Therapy for Traumatic Brain Injury
Furthermore, regarding adverse events, favorable results have been obtained in large-scale clinical trials. In the aforementioned SB623 trial, no new safety concerns were identified, and the most frequently observed adverse event was headache. These headaches were transient (occurring within 7 days post-procedure), and the difference compared to the control group was also reported as not statistically significant.
Tissue Regeneration in the Damaged Area
Specifically, no particular adverse effects of concern have been identified when compared to conventional surgical procedures. Indeed, several clinical trials have reported no serious adverse events, demonstrating its safe applicability. Some patients may experience transient fever, headache, or pain at the injection site following infusion or injection into the cerebrospinal fluid. However, these manifestations are indicative of the body's response to the treatment and are predominantly mild, self-limiting symptoms that typically resolve within a few days.
Transplanted stem cells facilitate a form of "brain repair." These stem cells differentiate into neural or vascular cells as needed, generating new cells and filling gaps in damaged tissue. Imagine a construction crew repairing potholes in a road. Stem cells are akin to the workers in this repair process, producing new cells (like laying fresh asphalt) incrementally, and seamlessly resurfacing the "potholed road" (brain circuits). Through this mechanism, brain tissue, which is otherwise considered non-regenerative, is restored, potentially leading to functional recovery.
Stem cell therapy is administered under the stringent oversight of medical facilities, where meticulous cell quality and infection screenings are rigorously conducted prior to treatment. Furthermore, post-treatment observation is maintained to ensure a prompt response to any changes in the patient's condition. Overall, the safety profile of stem cell therapy is exceptionally high, with a minimal risk of adverse effects. Consequently, patients can proceed with treatment with full confidence.
Activating Surrounding Cells
Stem cells not only differentiate into new cells but also act as a conductor, signaling surrounding cells to "collaborate for repair!" Indeed, it is reported that substances such as cytokines and growth factors released from stem cells promote the survival of surrounding nerve cells and activate the function of endogenous neural stem cells within the brain. Analogously, stem cells become the "leader of a reconstruction team dispatched to a damaged city," engaging with the residents (remaining cells) in the vicinity to stimulate the overall recovery of the city (overall improvement in brain function).
Conclusion
Over-suppression of inflammation (Immune Modulatory Action)
Traumatic Brain Injury (TBI) has traditionally been viewed as leaving behind untreatable long-term disabilities after the initial injury. However, with the advent of regenerative medicine's stem cell therapies, the brain now has an opportunity for recovery. Stem cells interact with the injured brain, mitigating inflammation, replenishing necessary cells, and collaborating with the surrounding environment to facilitate repair—effectively serving as the body's intrinsic repair specialists.
In Traumatic Brain Injury (TBI), the body's immune system is activated immediately post-injury, initiating an inflammatory response. While a moderate inflammatory response is necessary to address the damaged area, excessive inflammation leads to "secondary injury," which further harms brain cells. In this context, stem cells play a crucial inhibitory role, modulating the detrimental immune response. Specifically, Wharton's Jelly-derived Mesenchymal Stem Cells (WJ-MSCs) have been confirmed to possess prominent anti-inflammatory effects by suppressing pro-inflammatory substances (cytokines) and alleviating swelling and tissue damage. Simply put, much like a firefighter dousing an unnecessarily spreading blaze, stem cells extinguish this inflammatory "fire." Consequently, the cerebral microenvironment is stabilized, establishing conditions conducive to healing.
Its potential seems almost magical, and indeed, instances of "miraculous" improvements have been reported in clinical studies. Nevertheless, stem cell therapy is not magic; it is a cutting-edge medical treatment grounded in science. Research is continually advancing worldwide, and the technology evolves daily.
Furthermore, stem cells possess the ability to precisely control immune function and actively prevent their identification as foreign bodies, thereby avoiding attack. Consequently, transplanted stem cells readily engraft and can be safely utilized for therapeutic purposes. Thus, stem cell therapy exerts multifaceted effects on the damaged brain. These actions—including the repair of damaged areas, the supply of new cells, the release of paracrine repair signals, and the suppression of excessive inflammation—make it possible to improve brain functions that were previously considered irrecoverable. It can truly be asserted that "stem cells are the body's intrinsic repair and regulatory specialists."
In Japan, these treatments are currently not covered by insurance within the private healthcare sector. However, the environment is evolving to incorporate treatments supported by data accumulated both domestically and internationally. If you or a family member are struggling with post-TBI disabilities, we encourage you to consider consulting our institution. Our institution provides cutting-edge treatments utilizing Wharton's jelly-derived mesenchymal stem cells (WJ-MSC), and develops optimal, personalized treatment plans tailored to each patient's unique situation.
Evidence of Effectiveness of Stem Cell Therapy for Traumatic Brain Injury
Why not embrace new possibilities without relinquishing hope? Stem cell therapy holds the potential to be a powerful ally in restoring a brighter future for patients. Through the continuous advancement of research, we are committed to delivering optimal therapeutic solutions for TBI patients and their families globally.
Clinical Trial Results for Chronic TBI Patients (SB623)
An international clinical trial utilizing the stem cell therapy "SB623," developed by the Japanese company Sanbio, demonstrated significant improvement in motor function among chronic TBI patients who were 6 months to several years post-injury. In this trial, 39.1% of the group receiving intracerebral stem cell transplantation achieved a large, clinically meaningful improvement in their Fugl-Meyer Motor Scale (FMMS) scores for paralyzed upper and lower extremities (+10 points or more), significantly exceeding the 6.7% observed in the control group.
Experts commented that the findings of this experiment are highly groundbreaking, demonstrating the potential for damaged brains to regenerate. This provides evidence that regenerative medicine is effective even for chronic neurological conditions previously considered intractable. Stem cell therapy has thus emerged as a novel therapeutic option for brain conditions previously deemed beyond recovery.
In this trial, the observed improvements were not transient, and significant recovery was reported to be maintained even at a 1-year follow-up. In other words, the gains in motor function achieved through stem cell therapy persisted for at least one year, and the level of independence in activities of daily living improved.
For patients and their families, the prospect of improved brain function, even after a considerable period, offers immense hope.
In this context, the restoration of function has been confirmed in several studies, and its overall safety profile is also considered favorable. Naturally, as each study varies in scale and design, there are variations in the observed levels of effectiveness. Crucially, however, there have been no reports indicating a deterioration of conditions following stem cell therapy; on the contrary, specific improvements have been demonstrated.
